Avid Bioservices Q1 FY 2025: Revenue Up, Loss Widens
Avid Bioservices, Inc. (NASDAQ: CDMO) reported results for the first quarter of fiscal year 2025. The contract development and manufacturing organization (CDMO) posted 6% revenue growth to $40.2 million, driven largely by higher process development work. That momentum points to steady demand for the company’s services and room to build from here.
Financial Performance Overview
Revenue grew, but the company posted a net loss of $5.5 million. The shortfall reflects higher selling, general, and administrative (SG&A) expenses. CEO Nick Green highlighted a record $219 million backlog fueled by new project agreements, underscoring a pipeline that management believes supports the path ahead.
Key Financial Highlights
- Revenue rose to $40.2 million, up 6% year over year.
- Gross profit reached $5.7 million, equating to a 14% gross margin.
- SG&A expenses increased by 30%, primarily from higher compensation and consulting spend.
- Net loss widened to $5.5 million compared with the prior year’s deficit.
- Adjusted EBITDA came in at $3 million; cash on hand declined to $33.4 million.
- New project agreements totaled $66 million, contributing to a record backlog.
- CEO Nick Green discussed strategy with larger pharmaceutical customers and the ongoing challenges in cell and gene therapy.
Outlook for Growth
Management maintains a constructive view on growth, calling for improvements in adjusted EBITDA and margins as activity scales. The company sees potential for 40% to 60% incremental revenue if it can effectively fill remaining capacity. The plan: convert the growing backlog into higher revenue while steadily lifting margins.
Strategic Insights and Challenges
- The net loss increased to $5.5 million from $2.1 million year over year.
- SG&A rose 30% as the company adjusted to its current operating footprint.
- Cash reserves declined from $38.1 million to $33.4 million.
Positive Developments
Despite the pressure from operating costs, the company secured significant new work. The backlog reached a record $219 million on the strength of fresh project wins, signaling solid demand and creating room to diversify Avid’s customer base.
Operational Opportunities
- Gross margin improved from 11% to 14% this quarter.
- Most new projects came from new clients, pointing to healthy expansion.
Management Q&A Insights
In the Q&A, CEO Nick Green noted no meaningful change in demand from large pharmaceutical customers. He reiterated the company’s focus on execution and positioning, even as the cell and gene therapy market remains uncertain.
Challenges in Key Customer Segments
- Revenue from major customer Halozyme fell from a majority share to roughly one-third.
- Sales cycles with large pharma remain longer, which can delay project starts.
Conclusion and What Comes Next
The quarter reflects a mix of progress and pressure: higher revenue, better margins, and a record backlog on one side; higher SG&A, a wider net loss, and lower cash on the other. Management’s stance is steady—lean on the backlog, deepen customer relationships, and work to lift margins as capacity fills. The path isn’t simple, but the direction is clear.
Frequently Asked Questions
What did Avid Bioservices report for Q1 FY 2025?
Revenue was $40.2 million, up 6% year over year, and the company recorded a net loss of $5.5 million.
How did the net loss compare with the prior year?
The net loss widened to $5.5 million from $2.1 million in the same quarter last year.
What supports the company’s growth outlook?
A record $219 million backlog and the potential to fill remaining capacity underpin the outlook. Management sees 40% to 60% incremental revenue if that capacity is utilized.
Which costs and cash trends should I watch?
SG&A expenses rose 30%, and cash reserves declined to $33.4 million from $38.1 million. Both are key items to monitor as the company scales.
How are customer relationships evolving?
Most recent wins are with new clients, while demand from large pharma shows no major shifts. The company is balancing longer sales cycles with a strategy to diversify its customer base.
